(2S,3R)-3-(benzyloxy)-N-tert-butylpyrrolidine-2-carboxamide | 191850-15-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,3R)-3-(benzyloxy)-N-tert-butylpyrrolidine-2-carboxamide
• CAS: 191850-15-4
• 化学式: C₁₆H₂₄N₂O₂
• 分子量: 276.379
• InChiKey: TVAZKYPWXDRMHI-KGLIPLIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.85
• 重原子数：
  20.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  50.36
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  (2S,3R)-3-(benzyloxy)-N-isopropyl-1-(2,2,2-trifluoroacetyl)-pyrrolidine-2-carboxamide 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 以71%的产率得到(2S,3R)-3-(benzyloxy)-N-tert-butylpyrrolidine-2-carboxamide
  参考文献：
  名称：

  Synthesis of Polyhydroxylated Piperidine and Pyrrolidine Peptidomimetics via One-Pot Sequential Lactam Reduction/Joullié–Ugi Reaction

  摘要：

  A direct approach to the synthesis of poly-hydroxylated piperidine and pyrrolidine peptidomimetics is described. The presented strategy is based on one-pot reduction of sugar-derived lactams with Schwartz's reagent followed by a multicomponent Ugi-Joullie reaction.

  DOI：

  10.1021/acs.joc.5b00335

文献信息

• HIV protease inhibitors
  申请人：Wong Chi-Huey

  公开号：US06900238B1

  公开（公告）日：2005-05-31

  Combinatorial libraries of HIV and FIV protease inhibitors are characterized by α-keto amide or hydroxyethylamine core structures flanked by on one side by substituted pyrrolidines, piperidines, or azasugars and on the other side by phenylalanine, tyrosine, or substituted tyrosines. The libraries are synthesized via a one step coupling reaction. Highly efficacious drug candidates are identified by screening the libraries for binding and inhibitory activity against both HIV and FIV protease. Drug candidates displaying clinically useful activity against both HIV and FIV protease are identified as being potentially resistive against a loss of inhibitory activity due to development of resistant strains of HIV.

  HIV和FIV蛋白酶抑制剂的组合库以α-酮酰胺或羟乙基胺核心结构为特征，一侧为取代吡咯烷、哌啶或氮代糖，另一侧为苯丙氨酸、酪氨酸或取代酪氨酸。这些库是通过一步偶联反应合成的。通过筛选这些库，识别出对HIV和FIV蛋白酶的结合和抑制活性高效的药物候选化合物。对HIV和FIV蛋白酶都显示出临床有用活性的药物候选化合物被确定为潜在对抗由于HIV耐药株的发展而导致的抑制活性丧失。